Literature DB >> 10993553

Initial experience in the treatment of oral leukoplakia with high-dose vitamin A and follow-up 5-aminolevulinic acid induced protoporphyrin IX fluorescence.

A Leunig1, C S Betz, R Baumgartner, G Grevers, W J Issing.   

Abstract

The aim of photodynamic diagnostics is complete visualization of all neoplastic lesions in a tumorous organ after the application of a tumor-selective photosensitizer. We explored the potential benefit of a combination of retinyl palmitate for the treatment of oral leukoplakias and follow-up diagnosis of malignant tissue by using 5-aminolevulinic acid (5-ALA) as a fluorescence marker. Semiquantitative measurements were performed following the topical application of 5-ALA in six patients. After biopsy and histological evaluation of tissue specimens the patients were treated with escalating doses of retinyl palmitate. After treatment periods ranging from 4 to 8 weeks 5-ALA was again applied for photodetection of persisting fluorescence. In all cases prior to retinyl palmitate treatment a prominent red fluorescence indicated tissue dysplasia. Eight weeks after treatment with retinyl palmitate decreased red fluorescence intensities were found, and repeated histological evaluations showed no persistent signs of dysplastic lesions. Our initial experience shows that high doses of retinyl palmitate can be useful for treating dysplastic lesions in the upper aerodigestive tract and can be monitored with 5-ALA induced protoporphyrin IX fluorescence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993553     DOI: 10.1007/s004059900222

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  3 in total

1.  ALA (5-aminolevulinic acid)-induced protoporphyrin IX fluorescence in the endoscopic diagnostic and control of pharyngo-laryngeal cancer.

Authors:  Miklos Csanády; József G Kiss; László Iván; József Jóri; Jeno Czigner
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-09-03       Impact factor: 2.503

2.  A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia.

Authors:  Stuart J Wong; Bruce Campbell; Becky Massey; Denis P Lynch; Ezra E W Cohen; Elizabeth Blair; Rebecca Selle; Julia Shklovskaya; Borko D Jovanovic; Silvia Skripkauskas; Alexander Dew; Peter Kulesza; Vamsi Parimi; Raymond C Bergan; Eva Szabo
Journal:  Oral Oncol       Date:  2013-07-08       Impact factor: 5.337

3.  Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

Authors:  L Greenbaum; Y Gozlan; D Schwartz; D J Katcoff; Z Malik
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.